GlassScriptPhysician profile
Kevin S Price
NPI 1043241334
$1,770.90
in general payments reported to CMS, 2019-2025
14 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $241 · 2021: $119 · 2022: $104 · 2023: $95.25 · 2024: $75.11 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $321.10 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $285.72 | 2019-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $270.11 | 2019-2025 | |
| Abbvie INC. | $198.18 | 2022-2025 | |
| Axsome Therapeutics, INC. | $145.05 | 2025 | Auvelity |
| Alkermes, INC. | $105.95 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $101.07 | 2019 | |
| Vanda Pharmaceuticals INC. | $87.92 | 2019-2025 | Fanapt |
| Lundbeck LLC | $77.52 | 2019-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $70.98 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.54 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $30.19 | 2019-2025 | Austedo Xr |
| Allergan, INC. | $29.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.58 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.